Interim Phase 2a data with novel siRNA, RN0361
Interim Phase 2a results in study participants with hypertriglyceridaemia treated with a single dose of the quaternary Gal-NAc siRNA, RN0361, have shown dose dependent, clinically meaningful, durable reductions in apoCIII and TG levels for up to six months.
Read More > Interim Phase 2a data with novel siRNA, RN0361